News & Events
DR. MARTIN BELKIN TO SPEAK AT 2026 HOLISTIC HEALTH & WELLNESS FORUM FOR MS
Individuals living with multiple sclerosis (MS) and their care partners are invited to attend the 2026 Holistic Health & Wellness Forum for MS, presented by Yoga Moves MS. The program will feature national MS experts discussing integrative strategies that support whole-person wellness. Martin Belkin, MD, Medical Director of the MIND Multiple Sclerosis Center, will be among the featured speakers.
DR. DOTY FEATURED IN HEALIO Q&A ON ADVANCING MULTIPLE SCLEROSIS CARE
Dr. Jonathan Doty, neurologist at MIND, was featured in Healio discussing how advancements in multiple sclerosis treatment are enabling more personalized care, the importance of early and proactive therapy, and how integrated, specialized care models help improve long-term patient outcomes.
MIND RIVERVIEW CELEBRATES ONE YEAR OF EXPANDING ACCESS TO NEUROLOGICAL CARE
The Michigan Institute for Neurological Disorders (MIND) is proud to celebrate the one-year anniversary of its Riverview location, marking a year of growth, expanded services, and meaningful impact across the Downriver community.
DR. BELKIN FEATURED ON WWJ DURING MS AWARENESS MONTH
During Multiple Sclerosis Awareness Month, MIND Multiple Sclerosis Center Director Dr. Martin Belkin joined Tracey McCaskill on WWJ Radio’s Voices of the Community to discuss advancements in MS care, the importance of early diagnosis, and how MIND is supporting patients through comprehensive, specialized treatment.
MIND MS CENTER FEATURED IN DOWNRIVER PUBLICATIONS
MIND is featured in the March issue of the Riverview Register and Southgate Star during Multiple Sclerosis (MS) Awareness Month. The feature highlights how patients in the Downriver community can access specialized care at MIND’s MS Center and new Riverview location, emphasizing the importance of early diagnosis and access to experienced MS specialists.
MOVING MS CARE FORWARD
March is recognized as Multiple Sclerosis (MS) Awareness Month, a timely opportunity to highlight advances in diagnosis, treatment planning, and clinical research for a disease that impacts nearly one million people in the U.S.





































